<html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta http-equiv="Content-Style-Type" content="text/css" /><meta name="generator" content="Aspose.Words for .NET 13.4.0.0" /><title></title></head><body><div><p style="margin:0pt 0pt 12pt; text-align:center"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:bold">Written evidence from </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:bold">the UK Centre for Tobacco Control Studies (LTC 32)</span></p><p style="margin:0pt 0pt 12pt; text-align:justify"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">This submission is made on behalf of the UK Centre for Tobacco Control Studies, a UKCRC Public Health Research Centre of Excellence established in 2008 and comprising a network of leading tobacco control researchers from </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">ten</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> UK universities. </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">A full list of the researchers involved in the Centre, and </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">background information on the objectives and activity of the Centre</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">,</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">is </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">available at www.ukctcs.org.</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> </span></p><p style="margin:0pt 0pt 12pt; text-align:justify"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">Tobacco smoking is highly addictive and </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">the largest avoidable cause of ill-health, chronic disease and premature death in the UK. The adverse effects of smoking </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">contribute to the causation and/or exacerbation of all </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">of the chronic conditions listed by the Select Committee in this call for evidence, </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">with the possible exception of epilepsy. Preventing smoking is crucial to the primary and secondary prevention of these chronic conditions. </span></p><p style="margin:0pt 0pt 12pt; text-align:justify"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">As particular examples, smoking causes over 80% of Chronic Obstructive Pulmonary Disease (COPD) and lung cancer in the UK</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">,</span><a name="_ftnref1"></a><a href="#_ftn1">[1]</a><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">and smoking cessation is the only intervention that has a significant impact on disease progression in COPD. Around 20% of deaths from ischaemic heart disease, and 60% of those from aortic aneurysm,</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">are attributable to smoking</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">,</span><a name="_ftnref2"></a><a href="#_ftn2">[2]</a><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">and smoking prevention contributed more to the </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">decline </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">in mortality from heart disease in the UK over recent decades than </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">almost </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">all other interventions combined</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">.</span><a name="_ftnref3"></a><a href="#_ftn3">[3]</a><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">Smoking among people with mental health problems accounts for the majority of reduced life expectancy of this group,</span><a name="_ftnref4"></a><a href="#_ftn4">[4]</a><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> and has been particularly neglected; in contrast to the progressive downward trend in smoking prevalence, to around 20%, in the general</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">population, the prevalence of smoking among people with mental health problems has remained static at around 40% for the past two decades. </span></p><p style="background-color:#ffffff; margin:0pt 0pt 12pt; text-align:justify"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">Any strategy to improve and prevent morbidity and mortality from long term conditions should therefore have smoking prevention and harm reduction at its core. It is of particular importance to promote all population-level p</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">reventive strategies, including the use of price, media campaigns, smoke-free policies, preventing direct and indirect advertising and promotion (for example through smoking in films marketed to children and young people) and pursuing harm reduction strategies by making alternative sources of nicotine available to the general population. At individual level, it is also essential to build smoking cessation and harm reduction into the delivery of routine care for all chronic and long-term conditions. This is especially important for those with mental health problems, for whom smoking remains culturally accepted and even facilitated by healthcare professionals, who should instead be providing treatments and support to help smokers to quit. </span></p><p style="background-color:#ffffff; margin:0pt 0pt 12pt; text-align:justify"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">A recent joint report by the Royal College of Physicians and Royal College of Psychiatrists</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">, led by UKCTCS members but with contributions from over 30 experts,</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> drew attention to the major impact that smoking has in reducing quantity and quality of life among people with mental health problems. Key conclusions include: </span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 6pt 10.06pt; padding-left:4.14pt; text-align:justify; text-indent:0pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">Smoking is around twice as common among people with mental disorders, and more so in those with more severe disease</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 6pt 10.06pt; padding-left:4.14pt; text-align:justify; text-indent:0pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">Up to 3 million smokers in the UK, 30% of all smokers, have evidence of mental disorder and up to 1 million with longstanding disease</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 6pt 10.06pt; padding-left:4.14pt; text-align:justify; text-indent:0pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">One third of all cigarettes smoked in England are smoked by people with a mental disorder</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 6pt 10.06pt; padding-left:4.14pt; text-align:justify; text-indent:0pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">In contrast to the marked decline in smoking prevalence in the general population, smoking among those with mental disorder has changed little, if at all, over the past 20 years </span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 6pt 10.06pt; padding-left:4.14pt; text-align:justify; text-indent:0pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">Smokers with mental disorders are just as likely to want to quit than those without, but are more likely to be heavily addicted to smoking, to anticipate difficulty quitting smoking, and are historically much less likely to succeed in any quit attempt</span></li></ul><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 6pt 10.06pt; padding-left:4.14pt; text-align:justify; text-indent:0pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">Smoking cessation interventions that combine behavioural support with cessation pharmacotherapy that are effective in the general population are also likely to be effective in people with mental disorders </span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 6pt 10.06pt; padding-left:4.14pt; text-align:justify; text-indent:0pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">Smoking cessation does not exacerbate symptoms of mental disorders, and improves symptoms in the longer term </span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 6pt 10.06pt; padding-left:4.14pt; text-align:justify; text-indent:0pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">Smokers who do not want to quit smoking, or else feel unable to make a quit attempt, should be encouraged to cut down on smoking, and to use NRT or other nicotine-containing devices (in line with NICE tobacco harm reduction guidance) to support smoking abstinence in secondary care or other smoke-free settings, and promote the likelihood of future quit attempts. </span></li></ul><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 6pt 10.06pt; orphans:0; padding-left:4.14pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">Smoking is however a widely accepted component of the culture of many mental health settings, making cessation more difficult for smokers </span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 6pt 10.06pt; orphans:0; padding-left:4.14pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">Smoke-free policies are a vital means of changing this culture </span></li></ul><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 6pt 10.06pt; padding-left:4.14pt; text-align:justify; text-indent:0pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">Provision of effective smoking cessation and harm reduction support for smokers is crucial in maintaining smoke-free policy</span></li></ul><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 6pt 10.06pt; orphans:0; padding-left:4.14pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">The NHS spends approximately £720 million per annum in primary and secondary care treating smoking-related disease in people with mental disorders. </span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 6pt 10.06pt; orphans:0; padding-left:4.14pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">These costs arise from an annual estimated 2.6 million avoidable hospital admissions, 3.1 million GP consultations, and 18.8 million prescriptions.</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 6pt 10.06pt; orphans:0; padding-left:4.14pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">The majority of these service costs arise from people diagnosed with anxiety and/or depression.</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 6pt 10.06pt; orphans:0; padding-left:4.14pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">Smoking increases psychotropic drug costs in the UK by up to £40 million per annum. </span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 6pt 10.06pt; orphans:0; padding-left:4.14pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">Achieving cessation in 25%, 50% and 100% of people with mental disorder would respectively result in a gain of 5.5 million, 11 million and 22 million undiscounted life years in the UK. At 3.5% discounting, the corresponding figures are 1.4, 2.7 and 5.4 million life years gained.</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 6pt 10.06pt; orphans:0; padding-left:4.14pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">Harm reduction through lifelong substitution with medicinal nicotine is highly cost-effective when compared to continuing smoking, at around £8,000 per QALY gained for lifetime nicotine patch use and £3,600 per QALY for inhalators. </span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 12pt 10.06pt; orphans:0; padding-left:4.14pt; text-align:justify; text-indent:0pt; widows:0"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">Addressing the high prevalence of smoking in people with mental disorder offers the potential to realise substantial cost savings to the NHS, as well as benefits in quantity and quality of life. </span></li></ul><p style="background-color:#ffffff; margin:0pt 0pt 12pt; text-align:justify"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">Recent draft guidance published by the National Institute for Clinical Excellence on smoking cessation in secondary care settings,</span><a name="_ftnref5"></a><a href="#_ftn5">[5]</a><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> and on tobacco harm reduction,</span><a name="_ftnref6"></a><a href="#_ftn6">[6]</a><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> provide the practical guidance necessary to ensure that smoking cessation interventions become properly integrated into NHS care delivery. We recommend that the Committee considers this guidance, and ways to ensure implementation, and particularly in relation to mental health settings, in its review of services for chronic and long-term conditions. </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">Preventing smoking probably has more to offer in terms of preventing and ameliorating long-term conditions than any other measure. </span></p><p style="margin:0pt 0pt 12pt; text-align:justify"><a name="_GoBack"></a><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">The UKCTCS is an ESRC funded Investment. The views and statements expressed are those of the authors and do not necessarily reflect the views of the ESRC</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:bold">.</span></p><p style="margin:0pt 0pt 12pt; text-align:justify"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-style:italic">May 2013</span></p></div><hr style="width:33%; height:1px; text-align:left" /><p style="margin:0pt 0pt 0pt 27pt; text-align:justify; text-indent:-27pt"><a name="_ftn1"></a><a href="#_ftnref1">[1]</a><span style="font-family:Calibri; font-size:11pt"> </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">Twigg L, Moon G, Walker S. The smoking epidemic in England. London: Health Development Agency; 2004</span></p><p style="margin:0pt 0pt 0pt 27pt; text-align:justify; text-indent:-27pt"><a name="_ftn2"></a><a href="#_ftnref2">[2]</a><span style="font-family:Calibri; font-size:11pt"> </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">Twigg L, Moon G, Walker S. The smoking epidemic in England. London: Health Development Agency; 2004</span></p><p style="margin:0pt"><a name="_ftn3"></a><a href="#_ftnref3">[3]</a><span style="font-family:Calibri; font-size:10pt"> </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">Unal B, Critchley JA, Capewell S. Explaining the Decline in Coronary Heart Disease Mortality in England and Wales Between 1981 and 2000. </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt; font-style:italic">Circulation</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt"> 2004;109:1101-1107.</span></p><p style="margin:0pt"><a name="_ftn4"></a><a href="#_ftnref4">[4]</a><span style="font-family:Calibri; font-size:10pt"> </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">Royal College of Physicians, Royal College of Psychiatrists. Smoking and mental health. London: RCP; 2013</span></p><p style="margin:0pt 0pt 0pt 27pt; text-align:justify; text-indent:-27pt"><a name="_ftn5"></a><a href="#_ftnref5">[5]</a><span style="font-family:Calibri; font-size:11pt"> </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">National Institute for Clinical Excellence. Smoking cessation in secondary care: acute, maternity and mental health services. NICE: http://www.nice.org.uk/nicemedia/live/13017/63459/63459.pdf; 2013</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt"> </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">(accessed 23 Apr. 2013)</span></p><p style="margin:0pt"><a name="_ftn6"></a><a href="#_ftnref6">[6]</a><span style="font-family:Calibri; font-size:10pt"> </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">National Institute for Clinical Excellence. Tobacco - harm reduction. NICE: http://guidance.nice.org.uk/PHG/Wave23/23; 2012</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt"> </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">(accessed 27 Feb. 2013)</span></p></body></html>